Viking Therapeutics, Inc. (VKTX) witnessed a remarkable surge in its stock value following the promising data from its new obesity drug, which demonstrated strong metabolic improvements in clinical trials. This advancement marks a significant milestone for Viking Therapeutics as their drug offers potential for addressing the ongoing obesity epidemic with its effective metabolic enhancements. The trial results revealed notable improvements in weight reduction and metabolic markers, positioning the drug as a competitive player in the obesity treatment market. Investors showed confidence in the promising future of the drug, fueling the sharp increase in VKTX stock. With obesity continuing to be a serious health challenge globally, the successful development of this drug could provide a new therapeutic option for millions. Viking Therapeutics’ continued research and innovation in metabolic therapies underscore their commitment to advancing healthcare solutions.
parameter.ioNew data shows an 18% drop in suicide rates since 988 launch
June 24, 2026
A new report reveals an encouraging 18% decrease in suicide rates across the United States since the introduction of the 988 Suicide & Crisis Lifeline.